The US Food and Drug Administration has approved lenacapavir, marketed as Yeztugo by Gilead Sciences, as a twice-yearly injection to prevent HIV. The approval was based on clinical trials in which 99.9% of participants remained HIV negative. Calling it a significant step in HIV prevention efforts, the World Health Organization (WHO) welcomed the FDA's decision.